| Literature DB >> 30442731 |
Michael B Streiff, Bjorn Holmstrom, Dana Angelini, Aneel Ashrani, Paula L Bockenstedt, Carolyn Chesney, John Fanikos, Randolph B Fenninger, Annemarie E Fogerty, Shuwei Gao, Samuel Z Goldhaber, Krishna Gundabolu, Paul Hendrie, Alfred I Lee, Jason T Lee, Janelle Mann, Brandon McMahon, Michael M Millenson, Colleen Morton, Thomas L Ortel, Sadat Ozair, Rita Paschal, Sanford Shattil, Tanya Siddiqi, Kristi J Smock, Gerald Soff, Tzu-Fei Wang, Eliot Williams, Anaadriana Zakarija, Lydia Hammond, Mary A Dwyer, Anita M Engh.
Abstract
Venous thromboembolism (VTE) is common in patients with cancer and increases morbidity and mortality. VTE prevention and treatment are more complex in patients with cancer. The NCCN Guidelines for Cancer-Associated Venous Thromboembolic Disease outline strategies for treatment and prevention of VTE in adult patients diagnosed with cancer or in whom cancer is clinically suspected. These NCCN Guidelines Insights explain recent changes in anticoagulants recommended for the treatment of cancer-associated VTE.Entities:
Mesh：
Substances：
Year: 2018 PMID： 30442731 DOI： 10.6004/jnccn.2018.0084
Source DB: PubMed Journal: J Natl Compr Canc Netw ISSN： 1540-1405 Impact factor: 11.908